AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2005691
Drug: Intravesical BCG
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG (50 mg weekly for 6 weeks, at 8, 10, and 12 weeks, at 6 months and every 6 months thereafter)
Trial: 2005691
Drug: Intravesical plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical plus percutaneous BCG (50 mg intravesical BCG weekly for 6 weeks, at 8, 10, and 12 weeks, at 6 months and every 6 months thereafter)
Trial: 24610312
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (SJW) co-administered with boceprevir
Trial: 22460142
Drug: Tofacitinib 1
RxNorm normalized name: tofacitinib 11 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 1 mg
Trial: 20149584
Drug: Ginger extract
RxNorm normalized name: ginger extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger extract (120 mg)
Trial: 20149584
Drug: Control (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1 g of coconut oil as placebo)
Trial: 18497189
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotion program (tooth brushing 2 times/day, use of fluoridated toothpastes, dental care visits)
Trial: 15812606
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) in combination with fluvoxamine
Trial: 15812606
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) in combination with placebo
Trial: 15812606
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) in combination with fluvoxamine or placebo
Trial: 12420344
Drug: Chitosan (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan (750 mg pure chitosan per tablet, two tablets three times daily before each main meal)
Trial: 12420344
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical placebo tablets)
Trial: 7653757
Drug: Vecuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.3 mg administered into the systemic circulation at 10% recovery (Group 2)
Trial: 7653757
Drug: Vecuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.3 mg given when twitch height recovered to 50% depression (Group 3)
Trial: 1952297
Drug: Pentigetide nasal
RxNorm normalized name: pentigide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentigetide nasal solution (1 mg into each nostril four times daily)
Trial: 1952297
Drug: Pentigetide nasal
RxNorm normalized name: pentigide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentigetide nasal solution
Trial: 6820917
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of MMC immediately after operation
Trial: 6820917
Drug: Futraful for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Futraful for one year after MMC administration
Trial: 6820917
Drug: Futraful (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Futraful (dosage increase)
Trial: 6820917
Drug: MMC and
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC and futraful combination
Trial: 20601741
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (isoleucine:leucine:valine = 1:2.3:1.2) at 100 mg/kg body weight
Trial: 20601741
Drug: Placebo (dextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dextrin at 100 mg/kg body weight)
Trial: 8960576
Drug: L-NMMA administration
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA administration
Trial: 8251721
Drug: 100ml Naoxuenin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100ml Naoxuenin (NXN) oral liquid with conventional treatment
Trial: 8251721
Drug: Current conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current conventional treatment
Trial: 3762902
Drug: Lysine vasopressin
RxNorm normalized name: Lysine vasopressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lysine vasopressin (0.4 ml, 23 IU per day in 3 divided doses for 15 days)
Trial: 3762902
Drug: Desmopressin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (0.2 ml, 20 micrograms per day in a single dose for 15 days)
Trial: 3762902
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered by nasal route)
Trial: 29087796
Drug: Mouthwash prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash prepared from Pomegranate extract, 15 ml twice a day
Trial: 29087796
Drug: Mouthwash prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash prepared from Grape seed extract, 15 ml twice a day
Trial: 29087796
Drug: Mouthwash prepared
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash prepared from Guava extract, 15 ml twice a day
Trial: 29087796
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - Distil water, twice a day
Trial: 27581531
Drug: Monitoring group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring group (oral prasugrel 5 mg daily with dose or drug adjustment)
Trial: 27581531
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (oral prasugrel 5 mg daily with no monitoring or treatment adjustment)
Trial: 20034605
Drug: AS03(A)-adjuvanted H1N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)-adjuvanted H1N1 vaccine containing 5.25 microg haemagglutinin (HA)
Trial: 20034605
Drug: Non-adjuvanted H1N1
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted H1N1 vaccine containing 21 microg HA
Trial: 20034605
Drug: AS03(A)-adjuvanted H1N1
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(A)-adjuvanted H1N1 vaccine
Trial: 20034605
Drug: Non-adjuvanted H1N1
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted H1N1 vaccine
Trial: 17697209
Drug: AT-1001 (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-1001 (12 mg)
Trial: 11852667
Drug: Pravastatin 10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10-20 mg/day for 12 weeks
Trial: 7780090
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of chemotherapy with rifampicin-isoniazid-ethambutol (ethambutol only for the first 6 months)
Trial: 7780090
Drug: 18 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 18 months of chemotherapy with rifampicin-isoniazid-ethambutol (ethambutol only for the first 6 months)
Trial: 30760581
Drug: Fevipiprant (DP2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fevipiprant (DP2 antagonist)
Trial: 25073598
Drug: Autologous PRP
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous PRP therapy combined with a rehabilitation program
Trial: 25073598
Drug: Autologous PRP
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous PRP therapy
Trial: 22173851
Drug: Caffeine alone
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine alone (2.0 mg/kg)
Trial: 22173851
Drug: Alcohol alone
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol alone (0.6 g/kg)
Trial: 15970291
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Raloxifene, Estradiol valerate plus dienogest, Soy isoflavones)
Trial: 9468233
Drug: Amitriptyline 50
RxNorm normalized name: amitriptyline 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 50 mg taken at bedtime
Trial: 28634822
Drug: EPA (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA (1800 mg/day)
Trial: 26445565
Drug: Turkish coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turkish coffee (3 mg·kg(‐1) BW of caffeine)
Trial: 19425467
Drug: Glyconutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyconutritional supplement
Trial: 15745291
Drug: Passive continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive continuous infusion by gravitational force (Group 1)
Trial: 15745291
Drug: Manually controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually controlled pressure bag infusion at about 40 mmHg (Group 2)
Trial: 12227872
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide (Triaz 6% special gel), applied twice daily for 14 days
Trial: 12227872
Drug: Clindamycin (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (1% clindamycin phosphate in Cleocin-T lotion), applied twice daily for 14 days
Trial: 9231932
Drug: Toremifene (TOR)
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toremifene (TOR) 60 mg daily
Trial: 8280654
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 40 mg daily
Trial: 3307390
Drug: Peripheral iv
RxNorm normalized name: Soluline 7-Day Peripheral IV Line Supply
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral iv infusion of a 900 mosmol amino acid-glucose solution (2 L/day) for 21 days
Trial: 11680575
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ribavirin/day (group A)
Trial: 11680575
Drug: 1,000-1,200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000-1,200 mg ribavirin/day (group B)
Trial: 29150328
Drug: AAFP 500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAFP 500mg daily plus 4mg methylprednisolone BID
Trial: 29150328
Drug: OAA 1000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAA 1000mg daily plus 5mg prednisone BID
Trial: 26458911
Drug: CogniPlus training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CogniPlus training (20 sessions, twice a week)
Trial: 26458911
Drug: Physical training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical training (30 min daily for 10 weeks)
Trial: 19688282
Drug: Occupational therapy-led
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy-led lifestyle intervention
Trial: 8610286
Drug: Pericardial closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pericardial closure with PHB patch
Trial: 8610286
Drug: No pericardial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pericardial patch (control group)
Trial: 1782306
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg b.d.
Trial: 1782306
Drug: Famotidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (20 mg) b.d.
Trial: 24306134
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 g/kg for males, 0.75 g/kg for females)
Trial: 19683086
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose given 5 years post-primary vaccination (Group Y5)
Trial: 19683086
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose given 10 years post-primary vaccination (Group Y10)
Trial: 28079517
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of candesartan and rosuvastatin
Trial: 28079517
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of candesartan and rosuvastatin
Trial: 10065905
Drug: Antipsychotic drugs
RxNorm normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic drugs (neuroleptics, major tranquillizers)
Trial: 7909402
Drug: Best 'drug'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best 'drug' therapy (class I or class III antiarrhythmic therapy)
Trial: 27856288
Drug: aCT1 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aCT1 gel formulation plus conventional standard of care protocols
Trial: 25588457
Drug: Single hyaluronate
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single hyaluronate injection (HI group)
Trial: 22359979
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg once a week or Ibandronate 50 mg once a month
Trial: 15641878
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of risperidone and paroxetine
Trial: 10944645
Drug: Individualized counseling
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized counseling aimed at limiting fat intake to 30% to 35% of daily energy, with a saturated:monounsaturated:polyunsaturated fatty acid ratio of 1:1:1 and cholesterol intake of less than 200 mg/d (n = 540)
Trial: 8628561
Drug: 0.1% DfNa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% DfNa eye drops three times daily
Trial: 1481685
Drug: Branched-chain amino
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain amino acids (BCAAs) supplementation (7.5-12 g) during exercise
Trial: 31047687
Drug: Intravenous tissue‐plasminogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue‐plasminogen activator (IV tPA)
Trial: 31047687
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment decisions (IV tPA and MT)
Trial: 25808292
Drug: Free combination
RxNorm normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free combination of BDP pMDI and FF pMDI
Trial: 21725513
Drug: Dopamine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine with saline solution before endoscopic biliary drainage (n=64)
Trial: 21725513
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution alone before endoscopic biliary drainage (n=38)
Trial: 21725513
Drug: Additional dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional dopamine administration during the postdrainage phase (n=31)
Trial: 21725513
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional dopamine administration during the postdrainage phase (n=33)
Trial: 23086020
Drug: Guanfacine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (1 mg)
Trial: 18025315
Drug: Spray (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray (n = 63)
Trial: 12423708
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg/day) added to ongoing statin therapy
Trial: 10890228
Drug: Pentaglobin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaglobin (5 ml/kg body weight intravenously each day for 5 days)
Trial: 10890228
Drug: Placebo (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5% glucose solution with 1% human albumin, 5 ml/kg body weight intravenously each day for 5 days)
Trial: 8688309
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH), 50 IU/kg (n = 101)
Trial: 1707570
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with nitrosomethylurea, vincristine, and peplomycin
Trial: 1707570
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with nitrosomethylurea, vincristine, and bleomycetin
Trial: 1707570
Drug: Single-agent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent treatment with dacarbazine
Trial: 7049819
Drug: Dilazep 300
RxNorm normalized name: dilazep
DrugBank: Dilazep (DB13715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilazep 300 mg/die
Trial: 7049819
Drug: Nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 30 mg/die
Trial: 19834467
Drug: Successful aging
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful aging (SA) intervention involving weekly educational workshops
Trial: 18453642
Drug: Multimodal intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal intervention (Taiji exercises, cognitive-behavioral therapies, support group)
Trial: 12877571
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg (formulation A)
Trial: 12877571
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg (formulation B)
Trial: 12877571
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg (formulation A)
Trial: 12877571
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation 500 mg (formulation C)
Trial: 12877571
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation 750 mg (formulation B)
Trial: 8889283
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg moclobemide b.i.d. for 16 days
Trial: 8889283
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg selegiline b.i.d. for 16 days
Trial: 8889283
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of moclobemide and selegiline
Trial: 1905394
Drug: Lactobacillus GG‐fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG‐fermented milk product, 125 g (10(10‐11) colony‐forming units) twice daily (group 1)
Trial: 1905394
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG freeze‐dried powder, one dose (10(10‐11) colony‐forming units) twice daily (group 2)
Trial: 1905394
Drug: Placebo, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, a pasteurized yogurt, 125 g twice daily (group 3)
Trial: 6359379
Drug: Pneumovax (14-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumovax (14-valent pneumococcal vaccine)
Trial: 8083452
Drug: nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nedocromil sodium (4 mg) four times a day for 10 weeks
Trial: 17466698
Drug: 17-alpha-hydroxyprogesterone caproate
RxNorm normalized name: 17-alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-alpha-hydroxyprogesterone caproate (17P) 341 mg intramuscularly, twice each week until gestational week 36
Trial: 11583724
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone replacement therapy (17 beta E(2)‐D and CEE‐N)
Trial: 3521487
Drug: 8% arildone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% arildone cream
Trial: 29552942
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg leuprorelin acetate (LA) (n = 40)
Trial: 29552942
Drug: 1.88 mg
RxNorm normalized name: glycine 1.88 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.88 mg leuprorelin acetate (LA) (n = 40)
Trial: 29552942
Drug: Mirena implantation
RxNorm normalized name: Mirena Drug Implant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirena implantation after treatment with 3.75 mg LA (n = 40)
Trial: 29552942
Drug: Mirena implantation
RxNorm normalized name: Mirena Drug Implant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirena implantation after treatment with 1.88 mg LA (n = 20)
Trial: 29552942
Drug: San-Jie-Zhen-Tong capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: San-Jie-Zhen-Tong capsules alone (n = 20)